- Improving the health of people experiencing homelessness with recent drug overdose: rationale for 1
- 2 and design of the Pharmacist and Homeless Outreach worker Engagement Non-medical
- Independent prescribing Rx (PHOENIx) pilot randomised controlled trial 3
- 4

ISRCTN 10585019 5

- 6
- 7 Richard Lowrie^{1*}, Andrew McPherson¹, Frances S Mair², Donogh Maguire³, Vibhu Paudyal⁴, Becky
- Blair¹, David Brannan⁵, Jane Moir¹, Fiona Hughes¹, Clare Duncan⁶, Kate Stock¹, Natalia Farmer⁷, Becci 8
- Ramage¹, Cian Lombard¹, Steven Ross⁸, Ailsa Scott⁸, George Provan⁸, Laura Sills⁹, Jennifer Hislop¹⁰, 9
- Andrea Williamson¹¹ 10
- 11

12 ¹Pharmacy Services, NHS Greater Glasgow and Clyde, Scotland, UK; ²General Practice and Primary Care, Institute of Health and Wellbeing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Scotland, UK; ³ Emergency 13 Medicine, Glasgow Royal Infirmary, Scotland; ⁴ School of Pharmacy, University of Birmingham, England, UK. ⁵ Marie Trust, 14 Glasgow. ⁶ Addictions Psychiatry, NHS Ayrshire and Arran, Scotland; ⁷ Department of Social Work, School of health and life 15 sciences, Glasgow Caledonian University, Glasgow. 8Simon Community Scotland Street Team, Scotland, UK. 9 East End 16 Addictions Services, NHS Greater Glasgow and Clyde; ¹⁰ Healthcare Improvement Scotland ¹¹ Alcohol and Drug Recovery 17 Service, Glasgow Health and Social Care Partnership; ¹¹ Undergraduate Medical School, School of Medicine, Dentistry and 18 19 Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow.

- 20
- 21 *Corresponding author: Richard Lowrie, Lead Pharmacist, Homeless Health / Research and
- Development, NHS Greater Glasgow and Clyde, Glasgow, G76 7AT, Scotland, United Kingdom. Tel: 22
- +44 07971827565, email: Richard.Lowrie@ggc.scot.nhs.uk 23

25

ABSTRACT

26 Introduction

Numbers of People Experiencing Homelessness (PEH) are increasing worldwide. Systematic reviews 27 show high levels of multimorbidity and mortality due to treatable diseases including drug overdose. 28 Integrated health and social care outreach interventions may improve outcomes. No previous studies have 29 targeted PEH with recent drug overdose despite their high recorded levels of drug related deaths. There 30 are few data on health and social care problems. Feasibility work suggests a collaborative health and 31 social care intervention (Pharmacist and Homeless Outreach Engagement Non-medical Independent 32 33 prescriber Rx-PHOENIx) is potentially beneficial. We describe the methods of a pilot randomised controlled trial(RCT) with parallel process and economic evaluation in PEH with at least one drug-related 34 overdose in the preceding 6 months. 35

36 Methods

Detailed health and social care information will be collected at baseline before 1:1 randomisation to: care-37 as-usual plus visits from a pharmacist and homeless outreach worker (PHOENIx) for 6-9 months; or care-38 as-usual. The main outcomes are rate of presentations to emergency department(ED) for overdose or other 39 causes and whether to progress to a definitive RCT based on: recruitment of ≥ 100 participants within 4 40 months; $\geq 60\%$ patients remaining in the study at 6 and 9 months follow up; $\geq 60\%$ of patients in the 41 PHOENIx group receiving the intervention; and≥ 80% of patients with data collected. Secondary 42 outcomes include: hospitalisations; treatment uptake and patient reported measures. Semi-structured 43 interviews will explore future implementation of PHOENIx, and reasons for overdose and protective 44 factors. An economic evaluation will assess the feasibility of conducting a cost effectiveness analysis in a 45 subsequent definitive trial. 46

Discussion: The study will determine whether to proceed to a definitive RCT for PEH aiming to fulfil
unmet health and social care needs of those experiencing homelessness and at risk of drug related harms
and deaths while providing useful insights into barriers and facilitators to PHOENIx and characterising
the health and social care needs of PEH.

- 51 Ethics and dissemination: The trial was approved by the South East Scotland National Health Service
- 52 Research Ethics Committee 01. Results will be available in the last quarter of 2022.
- 53 **Registration details:** The trial is registered with the UK Clinical Trials Registry (ISRCTN 10585019).

54 Strengths and limitations of the study

- We plan to recruit patients normally excluded from intervention trials and collect a diverse health
- 56 and social care dataset at baseline
- 57 The 6-9 month individualised, complex intervention offers longer consultations, integrated
- 58 continuous, health and social care support on outreach
- 59 Mixed methods will enable determination of whether a subsequent trial is merited from an
- 60 efficacy, economic and patient perspective.
- By design, the pilot randomised controlled trial lacks the power to detect a clinically significant
- 62 effect and recruitment was limited to 20 locations in Scotland's largest city
- 63
- 64 Keywords: Pharmacy, Homelessness, randomised controlled trial, problem drug use.
- 65

67

INTRODUCTION

68 Background

Homelessness is a global problem, and the number of people experiencing homelessness (PEH) is 69 increasing worldwide.¹ The individual, societal, health and economic burden of homelessness is widely 70 known and undisputed.² The health of PEH is characterised by problems with mental health, physical 71 health, drug and alcohol use and PEH tend to die prematurely aged 41-51 years, with numbers of long 72 term conditions on a par with housed individuals almost twice their age.³⁻⁶ A majority of PEH experience 73 problem poly drug use, and associated high rates of deaths through overdose.^{7,8} Other causes of death are 74 also increasing.⁵ Homelessness is an independent risk factor for hospital admission and emergency 75 76 department (ED) attendance and rates of ED use are increasing across healthcare systems worldwide.² PEH are known to present to ED late and with comparatively more serious problems. ^{2,9} PEH can be 77 overwhelmed by their multiple health and social care problems and lack of support, experiencing 78 individual, structural and institutional difficulties with self-care.¹⁰⁻¹³ 79 80 The development and testing of complex, integrated health and social care interventions has been 81 highlighted as an important priority with the associated need to test the impact of longer contact times.^{2, 4,} 82 5, 14, 16 83

84

85 Complex interventions for multiple problems

Assertive outreach delivered by workers who can establish trust and develop positive interpersonal
relationships is an evidenced approach to strengthening primary health and social care for PEH. ¹⁴⁻¹⁷
Partnerships should be built between outreach health services and homeless service providers who are
best placed to support wider needs including housing, education and employment.¹⁴ PEH perspectives on
effective components of interventions include: involvement of peer workers in outreach programmes; help
with housing; welfare payments and social prescribing. ^{9, 14, 18, 19} Interventions limited to addressing single

health problems e.g. problem drug use, or mental health problems, may hold little appeal for PEH who

93 have multiple problems. ^{2, 15}

Interventions in published studies offered housing improvements for PEH with mental health or substance 94 misuse, or target and address single physical health conditions e.g. HIV or Tuberculosis without 95 addressing multimorbidity ^{16, 19-23} or diseases thought to be amenable to early intervention e.g. 96 cardiovascular or respiratory disease.⁵ Of the few robust studies of interventions led by healthcare 97 professionals aiming to improve broad outcomes e.g. mortality or reduced ED utilisation, none have been 98 found to be effective.²³ Interventions to address multiple needs in PEH are necessarily complex, with a 99 new framework supporting rigorous, phased testing.²⁴ We are not aware of studies having following the 100 101 recommended development stages for testing of complex interventions, including pilot testing to inform power and sample size calculation for a subsequent definitive trial.^{19, 24, 25} There are no UK based 102 intervention studies targeting community based PEH.²³ 103

104

105 A role for pharmacists collaborating with third sector homeless workers

Generalists may be best equipped to address the diverse levels of multimorbidity experienced by PEH, ⁴, 106 ^{15, 16} suggesting the testing of holistic medical plus social care on outreach for community dwelling PEH is 107 overdue. However, as workforce shortages worsened by COVID-19 may limit expansion of roles of 108 established primary care clinicians, there may be a role for pharmacists with generalist independent 109 clinical prescribing qualifications. Generalist Pharmacist independent prescribers exist across the world, 110 offering a potential solution to ongoing General Practitioner and Nurse workforce shortages.²⁶ Over 7500 111 (13%) of UK based pharmacists have undergone additional subsequent training in therapeutics and 112 completed a period of additional supervised clinical training, to gain an independent prescribing 113 qualification. This independent prescribing qualification enables diagnosis and prescribing for any 114 condition within the pharmacist's competency. In the UK, Pharmacists practise as part of the 115 multidisciplinary health team throughout primary care (in community pharmacies as independent 116 contractors or based in General Practice offices as clinical pharmacists) and secondary care. A 117

collaboration between Pharmacists and third sector homeless workers is likely to be welcomed by PEH. ¹⁰
Emerging evidence of under-treatment with medicines ^{3, 6} and challenges to medicine adherence, ²⁷ which
may be amenable to pharmacist intervention ^{28, 29} both of which may contribute to poor health and
premature death in PEH,^{2, 5} suggests a need to robustly test pharmacist led integrated health and social
care intervention for PEH.

123

124 **PHOENIx**

Staff working for homeless charities in Glasgow, Scotland (The Simon Community Scotland and The 125 Marie Trust) have lived experience of homelessness and formed a novel, integrated National Health 126 127 Service – Homeless sector partnership called PHOENIX: Pharmacist and Homeless Outreach Engagement and Non-medical Independent prescribing Rx.³⁰⁻³² The PHOENIx team assertively outreach 128 to various locations in Glasgow e.g. homeless congregate accommodation, to engage and offer holistic 129 assessment, treatment, prescribing and referral for patients' expressed health and social care priorities. ³⁰⁻ 130 ³² PHOENIx is a secondary prevention intervention aiming to improve self-care and strengthen primary 131 care to reduce the use of ED. The Pharmacist is from the National Health Service and the third sector 132 outreach worker is from either of Glasgow's homeless charities (Simon Community Scotland or the Marie 133 Trust). Visiting patients once weekly, and with consultations lasting an hour on average, previous 134 qualitative work suggests benefit to patients ³³ and a feasibility study describes the pharmacist assessing, 135 treating and prescribing for acute and chronic health problems, while the homeless charity link worker 136 addresses benefits, housing and social prescribing.³² Working within the clinical governance framework 137 provided by the patient's GP and the local ED, PHOENIx may improve health and reduce emergency 138 health service contacts. 32, 33 139

140

141 PHOENIx after overdose pilot randomised controlled trial

Here, we describe methods from an ongoing pragmatic pilot randomised controlled multicentre trial with
embedded economic and qualitative evaluation, of PHOENIx intervention targeting PEH with recent non-

144	fatal drug overdose. The trial aim is to determine whether progression to a subsequent definitive
145	randomised controlled trial is justified based on: reduction in ED visits; rate of participant recruitment and
146	retention at 6 and 9 month follow up; fidelity of intervention delivery; and sufficient data collection at
147	baseline and 6 and 9 month follow up. Given the paucity of data informing research and service delivery,
148	we will also collect a diverse range of patient level health and social care data. Secondary outcome data
149	include measures of overdose occurrence, healthcare utilisation, acceptability, and patient reported
150	outcomes (e.g. quality of life/perceived burden of treatment/levels of anxiety/depression).
151	
152	METHODS
153	Study setting
154	NHS Greater Glasgow and Clyde (GG&C) provides free primary, secondary and tertiary care to
155	approximately 1.2 million people (almost 25% of the Scottish population). Prior to the COVID-19
156	pandemic, there were an estimated 7000 PEH in Glasgow every year with an estimated 560 rough
157	sleeping annually, both proportions higher than in the rest of the UK. ³⁰ The study is set in 20 Glasgow
158	venues (homeless accommodation or drop in centres).
159	
160	Eligibility criteria
161	Participants
162	Homeless individuals ¹⁴ aged 18 years and over are considered eligible if they have at least one drug
163	overdose in the previous 6 months (Table 1).
164 165 166	Table 1: Trial Inclusion and Exclusion Criteria

Inclusion Criteria	Exclusion Criteria
Legally homeless (living in temporary homeless	Living in residential or community
accommodation, rough sleeping or threatened with	based rehabilitation facility which has
homelessness)	direct access to in-house medical and
and	nursing care
Aged 18 years and over	or

and	Unable to give written informed consent
One or more non prescribed drug overdoses in past six	
months confirmed by self-report and witnessed	
overdose/ambulance call out/ED visit /naloxone use	

167

168 **PHOENIx team**

The PHOENIx team comprise five part-time NHS Greater Glasgow and Clyde employee pharmacists working in pairs with four part-time Homeless charity link workers (from The Simon Community Scotland or The Marie Trust) available Monday to Friday, between the hours of 9am -6pm. Pharmacists are within the governance of a Homeless Health Service General Practice and a major teaching hospital in the city (Glasgow Royal Infirmary) ED clinical staff who provide clinical support. PHOENIx offers holistic, first contact, continuous primary health and social care, understanding that motivation fluctuates, and patients' trust in care providers is usually low due to previous traumatic life experiences e.g. assault,

abuse, or stigma.

Pharmacists in the PHOENIx team had undergone additional training and passed a theory and practical 177 examination in the appendix and clinical assessment, to qualify as independent prescribers, able to 178 prescribe any medicine within their competency. Pharmacists carry a kit bag containing: a prescription 179 pad; laptop for accessing clinical records; mobile phone; basic clinical equipment for common clinical 180 assessments; medicines for emergency purposes (salbutamol, aspirin, glyceryl trinitrate spray); wound 181 care products; lists of relevant health and social care contacts; naloxone and clean injecting equipment. 182 They have read and write access to patients' clinical records (addictions/mental health teams, Homeless 183 Health Service General Practice Hospital, community pharmacy dispensing) and the third sector 184 Homeless link worker has read and write access to wider third sector contacts. Working in pairs, the team 185 gather as much information as possible about each patient on first meeting, using medical and third sector 186 charity records, to understand the patient's priorities and inform an individualised intervention and in case 187 of any known risks. The pharmacist conducts a clinical assessment, then prescribes, refers or treats 188 patients on the spot. 189

190	The Homeless link workers remain employed as part of their parent charity organisation, although have
191	NHS honorary contracts. During consultations, the link worker offers to maximise the patient's incoming
192	financial benefits, improve access to better accommodation, encourage participation in social activities
193	and generally problem solve where possible in any other aspect of the patient's shared story while
194	building a therapeutic relationship.
195	In addition to clinical/technical expertise, selection procedure at interview for PHOENIx staff included
196	demonstration of empathy, non-judgemental attitude and active listening.
197	

198 Interventions

199 Usual care

In Scotland, PEH are offered a temporary single room in a designated city centre venue e.g. hotel, hostelor bed and breakfast accommodation, and allocated a named case worker.

Patients with problem alcohol or substance use may receive care and treatment from Glasgow's Alcohol
 and Drug Recovery Service (ADRS) or the Homeless Addictions Team (HAT) or the Heroin Assisted
 Treatment service. Patients can present to any ADRS seeking help and receive same day assessment. In
 some circumstances following management of any immediate care needs they may be supported to

engage with another ADRS closer to their temporary accommodation or to which they remain open from
a previous treatment episode. If transport to a different base is required at the time they present the service
will offer a taxi to facilitate this journey. For people already open to drug and alcohol services their care
and treatment is provided through a combination of phone and face to face contact either at the base or on
outreach, dependent on individual needs and circumstances.

To access primary health care including a General Practitioner, or ADRS, PEH must either travel to their registered mainstream or specialist homelessness General Practice or phone, which requires PEH to have

- access to a mobile phone (which can be supplied by ADRS or HAT) or use a landline within their
- accommodation, if appropriate. All mainstream services operated triage during COVID-19 lockdown,
- with requests for patients to phone the relevant care team prior to presenting at the premises, if possible.

216

The Homeless Health Service GP practice offered phone inreach to a variety of homeless accommodation
services and restarted outreach after a period of interruption.

219

220 For patients with mental health problems without problem drug use, access is through General

221 Practitioner referral to general mental health services or a request for support via ADRS if currently

- 222 linked in for treatment of problem substance use.
- 223

Clinical records for PEH are spread across three or four different platforms because different clinical teams (emergency care, specialist Homeless GP, mainstream GP, ADRS and mental health, social care) are distinct, each record system with different access privileges used by staff within each team. The Pharmacists in the PHOENIx team obtained permissions to remotely access all possible health and social care records on outreach, to understand all of the patients' previous health and social care history and relieve patients of the burden of repeating their traumatic stories again, and for safety reasons.

230

In the UK, the out-patient (ambulatory) management of PEH with chronic diseases takes place either 231 solely in primary care or between primary care and Hospital based out-patient clinics. During COVID-19 232 233 lockdowns most out-patient appointments were switched to phone or on line video consultations which may or may not have been possible for PEH. Patients in need of urgent hospital care self-present or may 234 be referred by their GP or others to a hospital ED from where they may be admitted to hospital or 235 discharged back to primary care. Prescribing is undertaken by GPs, and independent prescribers e.g. 236 pharmacists or nurses with advanced clinical skills and knowledge. All prescriptions are obtained free of 237 238 charge from community pharmacies. The capacity for outreach from services that PEH use is variable across the city. 239

240

241 Intended purpose of the PHOENIx intervention

242 The PHOENIx intervention aims to decrease emergency service use, and overdoses, by increasing access to holistic preventative primary health care and improving the socioeconomic factors associated with 243 homelessness e.g. income, housing. Offering weekly visits, on assertive outreach and through persistent 244 follow up, PHOENIx aims to provide 'whole person' help for all health and social care needs: physical 245 health; mental health; problem drug use; benefits; accommodation; and social prescribing.³⁰⁻³³ Access to 246 the team for any reason, was facilitated by a dedicated phone number which patients could call anytime, 247 248 or through the staff working for the Simon Community Scotland or the Marie Trust, who facilitated 249 contacts face to face. The team do not discharge any patient and all contacts were in addition to the 250 patient's usual care. If the team cannot locate patients they enquire in accommodation or other venues or 251 through contacts within homeless charities or statutory services, to help track PEH. The team are aware of barriers to accessing care among PEH, and the problems posed by segmentation of 252 services, so they adopted a person-centred, trauma informed approach. A comprehensive health and social 253 care assessment is offered on the first meeting with each patient unless the patient's priorities take the 254 conversation in another direction, in which case the assessment is conducted in stages thereafter. If the 255 team are unable to provide direct health/social care help immediately, they problem solved with the 256 patient, on the spot e.g. referred, or made an appointment on the patient's behalf e.g. to attend an 257 appointment with mental health team while booking transport and providing reminders. The PHOENIX 258 259 team treat patients as equal partners in discussions about their treatment and wishes, asking patients to prioritise what they want help with over the course of weekly visits for at least 6 months. For example, if 260 the patient does not want to tackle their drug use, this is not prioritised by the team. Instead, other 261 priorities e.g. mental health problems, or respiratory function, or financial benefits, or changing 262 accommodation, became the focus until the patient was ready to address their problem drug use. The team 263 provides a variety of supports at different times depending on the patient's needs including advocacy, 264 clothing, emotional support, phones, books, shopping, furniture,³¹ Patients injecting drugs will be 265 routinely offered dry blood spot BBV testing, injecting equipment and naloxone at each visit. Pharmacy 266 Services within NHS Greater Glasgow and Clyde will remain the Pharmacists' employers throughout the 267

- study: strong communication links between the pharmacists and all other clinical teams involved in thecare of PEH minimised any theoretical clinical risks.
- 270

271 The Intervention will be discontinued if the patient: loses capacity; enters a rehabilitation facility;

- becomes incarcerated and cannot not be reached in prison; becomes lost to follow up (some PEH flee
- violence and their whereabouts can suddenly change to prevent encounters with known assailants); or if
- the patient asks the team to stop offering the intervention.
- 275

The study Principal Investigator will visit pairs of PHOENIx staff on outreach every month and receive 276 277 feedback from teams to assess fidelity of the intervention against the intervention domains. The team will meet monthly to discuss progress and patient scenarios, forming a robust peer support network, with daily 278 communication through an encrypted social media channel approved for use by NHS Greater Glasgow 279 and Clyde. The pharmacists will meet with the Homeless Health Service GPs monthly to discuss difficult 280 cases and seek advice when necessary from the Homeless Health GP service and consultants in the ED of 281 282 the local hospital and homeless liaison nurses in the local hospital. There will be regular communication with ADRS/HAT staff. 283

284

All other interventions and concomitant care are permitted throughout the trial.

286

287 Outcomes

The co-primary endpoint is whether to progress to a definitive trial, based on any improvement in the rate of presentation to EDs for overdoses or other causes, during the 6 or 9 month follow up period, and achievement of the following progression criteria:


- recruitment of at least 100 patients within 4 months;
- ≥ 60% patients remaining in the study at 6 and 9 months follow up (excluding those who have
 died or lost capacity);

294	• establishment of the pharmacist intervention ($\geq 60\%$ of patients in the intervention group receiving
295	the intervention as planned excluding those who have died or lost capacity);
296	• \geq 80% of patients with data collected as planned (excluding those who have died or lost capacity).
297	Secondary outcomes are as outlined below, compared between Intervention and Usual care groups at 6
298	and 9 month follow up:
299	1. Health care utilisation which includes number of (and number of patients with):
300	• Non prescribed drug overdoses;
301	• hospital admissions;
302	• prescribing for multimorbidy (proportion of patients prescribed medicines for diagnosed conditions;
303	proportion of patients with minimum doses of medicines for diagnosed conditions);
304	• contacts (phone or face to face) with GP/nurse/addictions worker/other healthcare professional;
305	• Scottish Ambulance Service call outs;
306	• missed out-patient appointments.
307	2. Time from randomisation until: first ED visit for OD and other reasons; death; and hospitalisation.
308	3. Patient reported measures:
309	• EuroQol 5D 5L quality of life score ³⁴
310	• Patient Experience with Treatment and Self-management measure (PETS) ³⁵
311	• Frailty score ³⁶
312	Anxiety/depression ratings
313	Modified MRC breathlessness scale
314	
315	Outcomes will be collected by independent researchers interviewing patients and accessing NHS clinical
316	records at 6 and 9 month follow up compared between the intervention and usual care groups.
317	Intervention acceptability will also be measured through a parallel qualitative evaluation.
318	

319 **Participant timeline**

Time schedule for enrolment, interv assessments and visits for partici

Follow-up through NHS electronic records and patient inte Median follow- up 6 –9 months



320

321 Sample size

The guidance on sample sizes for pilot studies varies with 30-50 patients per arm thought to be sufficient, 322 because the focus is on estimating parameters for the full study, rather than formal testing of hypotheses.³⁷ 323 We aimed to invite approximately 160 patients, anticipating a recruitment rate of ~60% based on our earlier 324 feasibility study.³² If 100 agree to participate, we estimate the recruitment rate as 62.5% (95% CI 55%-325 70%). Mortality rate in our previous feasibility study was 8.3% over one year, therefore we anticipated 6 326 patients dving over 9 months.³² Assuming a conservative retention rate of 70% after 9 months, and 327 additional losses due to mortality, we anticipate at least 64 patients with 6 and 9 month follow up data to 328 inform sample size for a full scale randomised controlled trial. 329

- 331 Recruitment
- 332 The importance of researcher 'fit'

Induction training will include visits to potential study sites in Glasgow, and introductions to
accommodation staff and third sector street homeless outreach workers were in different venues.
Processes for obtaining consent and baseline and follow up interviews and data collection will also be
explained and rehearsed. The researchers comprise a qualified mental health nurse with more than 20
years of experience in front line NHS service delivery and research with PEH, and those experiencing
problem substance use and poor mental health; and a pharmacy technician with over 20 years' experience
in patient services (mental health and general hospitals).

- 340
- 341 Process

342 Researchers will visit accommodation and other venues, to approach all potentially eligible patients, face

to face. Patient self-report of overdose will be confirmed by examination of clinical records and/or

testimony from witnesses e.g. accommodation staff, friends, or injecting/drug using partners.

Confirmation included ambulance call out, naloxone administration recorded in clinical notes or in-house 345 patient records made by accommodation providers, or an ED visit for overdose. Researchers will ask each 346 347 potential recruit about the circumstances of the overdose, and when this occurred, including whether the patient had any recollection of having received any assistance from other people at the time of overdose. 348 This approach to identifying eligible patients will be taken because our collective clinical experience 349 350 suggested most non-fatal overdoses are not formally recorded or if recorded, there is no standardised. identifiable coding applicable across different clinical / administrative records. Patients will be offered a 351 non cash incentive (voucher for use in a city centre store not selling alcohol or tobacco) of £10 (equivalent 352 to 13 US dollars or 12 Euros) on completion of baseline data collection, and after completion of each 353 follow up data collection at months 6 and 9. The baseline interview pro-forma is shown in Supplementary 354 information. 355

356

357 Methods: assignment of interventions

Allocation: sequence generation One hundred and sixty sealed opaque envelopes will be generated
remotely by staff from the University of Birmingham not directly involved in participant recruitment.
Each envelope will contain a folded piece of paper with the computer generated printed words:
'PHOENIx Intervention' or 'Usual care'. The envelopes will be randomly shuffled, by staff from the
University of Birmingham then sent in a box, by secure mail, to the Glasgow study centre before the first
patient is recruited. This is an individual level randomisation approach without stratification.

364 Allocation concealment mechanism and implementation Researchers will take informed consent by 365 discussing the patient information leaflet with patients, explaining what the study entails, and asking if the patient would want to participate. Some patients will read the information and make the decision 366 367 themselves. In both cases, patients will have time to read the information or have it explained to them, and ask questions before coming to a decision. Researchers will conduct baseline interviews in person with 368 participants in different venues in Glasgow city centre. At the end of the interview researchers will phone 369 the study centre asking for a randomisation. One of the research team will answer the call immediately 370 and, in the presence of another member of the research team, pick an envelope at random from the box of 371 envelopes. The research team will request the following information from the researcher: patient name; 372 date of birth and location. A sequential study number will be written on the outside of the chosen 373 envelope and, in the presence of another member of the research team, and while the researcher remains 374 on the phone, the envelope will be opened and the allocation revealed to the researcher (and patient) on 375 the phone after two members of the research team read the allocation from the piece of paper inside the 376 envelope. The study team will return the piece of paper inside the envelope then write the words 377 'Intervention' or 'Usual care' onto the outside of the envelope together with the date and store the 378 envelope inside a folder (one folder per patient), inside a lockable filing cabinet within the study centre. 379 Participants will therefore be randomised in a one-to-one ratio to 'usual care' or 'PHOENIx intervention'. 380 On allocation to Intervention, the patient's details and location will be communicated to the PHOENIX 381 team who will be asked to contact the patient and begin offering the intervention. 382

383

- Following allocation to usual care, participants will have no further contact from study personnel until
- 385follow up data collection.
- **Blinding** Independent statisticians conducting analysis of follow up data will be blinded to allocation.
- 387 Assessment of outcomes from clinical records will be conducted by a researcher / administrator who will
- 388 be blind to assignment to intervention or usual care group.
- 389

390 Data collection, management and analysis

Baseline, six and nine month follow up data will be collected during researcher led face to face patient interviews in the patient's accommodation, or in homeless charity drop in centres in Glasgow city centre. Interviews will last approximately 45 minutes. Study instruments used during interviews e.g. weighing scales, peak flow meters, were used routinely during clinical care in primary and secondary care, and familiar to researchers.

Data to be collected (Supplementary information) include: details of comorbidities; non prescribed drug
use; prescribed medicines; health related quality of life using EQ-5D-5L; weight; height; Blood pressure;
Pulse; Peak Expiratory Flow rate; modified Medical Research Council Dyspnoea scale; COPD Assessment
Test; grip strength, GP visits, nurse visits, ADRS and mental health team and other primary healthcare
contacts; un/scheduled secondary healthcare contacts including missed out patient appointments; Fried's
Adapted frailty phenotype questions and an adapted version of the Patient Experience with Treatment and
Self-Management (PETS) measure.

The intervention team will record all treatment administered e.g. dressings changes, prescriptions issued, referrals; advice given; gifts and kindness e.g. personal support in form of clothing or food; advocacy and type (face to face or phone call) of patient visits.

Validated questionnaires used during interviews have not previously been used in PEH, therefore, the research and clinical team evaluated their suitability in advance and decided only one needed modification: The PETS.³⁵ Some aspects of the language used in the PETS and assumptions about how patients obtained their medicines and aspects of self-care were deemed potentially incomprehensible to PEH in Scotland,

which led to the research team making minor modifications, which were discussed with the questionnaire author. They included, for example, replacing the term "refill" in relation to medicines, to "get more of your medicines before they run out" or replacing "somewhat" with "neither easy nor difficult" or "monitor" with "keep tabs on" or "checking blood pressure" with "checking injection sites". The section containing five questions about "Medical and healthcare expenses" was omitted because the health service in Scotland does not charge for care and all prescriptions are free.

416

Interview data will be recorded on paper data collection forms during interviews, prior to transcription onto 417 an EXCEL spreadsheet by the research team. Prescribing, co-morbidities, laboratory test values, General 418 419 Practitioner contacts and other healthcare utilisation data will be subsequently extracted from medical and ADRS team records and entered onto the same EXCEL spreadsheet. We therefore plan to utilise data from 420 these two sources (patient reports and data from medical records) to provide a comprehensive picture. 421 Members of the research team will cross check a 10% sample of data entries for accuracy and completeness. 422 At 6 and 9 month follow up, the research team will make repeated attempts to re-engage patients, as will 423 the PHOENIx team during the intervention phase. Repeated attempts will be made weekly and in addition 424 to phone calls (if the patient has a phone) including: checking primary care clinical records for attendance 425 at health and social care venues for appointments and meeting the patient at the appointment; checking 426 427 emergency department and hospital records for presentations and changes to contact address and contact numbers or for change of status from having capacity to loss of capacity (reason for withdrawal from the 428 trial) or death; phone/visit to community pharmacies to ask if the patient has attended for collection of 429 prescription or for supervised opiate substitution treatment; phone/visit to the patient's accommodation to 430 enquire about the patient's usual patterns of appearance: asking the homeless community hub staff if 431 patient has attended; asking the third sector homeless outreach teams for possible sightings; and visiting 432 the patient's usual begging site. If patients cannot not be located, researchers will still be able to collect 433 patient data from hospital records, General Practices and Alcohol and Drug Recovery Services as 434

appropriate. If patients die or loose capacity, data up until the point of death or loss of capacity, will becollected.

437

438 Statistical methods

Outcome analysis will be conducted by independent statisticians at University of Birmingham after 439 collection of 9 month follow-up data. Primary outcome measures will be described using proportions, 440 441 along with 95% confidence intervals to describe uncertainty. Patient questionnaire and clinical measures 442 will be analysed according to the intention to treat principles. Appropriate summary statistics (e.g. proportions & inter-quartile ranges, means and standard deviations) along with 95% confidence intervals 443 444 will be generated for the study feasibility and patient reported / clinical / health utilisation measures. By design there is no a-priori powered endpoint, however hypothesis testing will be conducted to determine 445 whether there is any difference between outcome measures. Between-group measures (mean differences 446 and relative risks) will be reported with 95% confidence intervals. 447

448

449 Economic evaluation

An embedded economic evaluation will examine the feasibility of determining the cost-effectiveness of the 450 PHOENIx intervention in a subsequent definitive trial. The main analysis will consider a health and social 451 452 care service perspective whereby unit costs are applied to each item of health (e.g. hospitalisation) and social care service use data. Unit costs will be taken from routine sources where possible including missed 453 appointments. ³⁸⁻⁴⁰ The effectiveness of the intervention will be explored in terms of health state utilities 454 (for a future cost utility analysis), as measured using the EQ-5D-5L to generate Quality Adjusted Life Years 455 (QALYs) to be used alongside the cost data to give an indicative picture of cost-effectiveness. QALYs will 456 be generated from the EQ-5D-5L using appropriate crosswalk methods and applying reference values for 457 the EO-5D-3L.⁴¹⁻⁴³ Both cost and utility outcomes will be quantified to describe the costs of the services 458 and to provide QALY data, as currently few data on the QALY loss associated with homelessness are 459 available. 460

461

462 **Qualitative evaluation**

In a parallel process evaluation, we will explore participant perspectives of their drug use and overdoses, 463 464 including aspects of support perceived as most important in order to prevent subsequent drug overdose and their perceptions of the existing pathway for health and social care follow up post drug overdose together 465 with their experience of the intervention. This will be conducted through qualitative face-to-face semi 466 467 structured interviews with a purposive sample of 20-30 recruited patients in the intervention and usual care group in order to obtain a variety of experiences. Interviews will be conducted by an independent researcher 468 (NF) who has no knowledge of patients prior to the interviews. All interviews will be conducted in a city 469 470 centre drop in service utilised by PEH. Data will be gathered by recording face to face semi-structured interviews via an audio digital recording device and will be transcribed, using pseudonyms to ensure 471 confidentiality and anonymity. All study participants will receive a £10 voucher as recognition for their 472 participation. Thematic coding will be conducted by NF and then checked by members of the research team 473 to reduce the risk of bias, ensure consistency and rigour. Normalisation Process Theory (NPT) will be used 474 475 to inform conceptualisation of the process evaluation data because it is a theoretical framework used to aid development, evaluation and implementation of complex interventions. NPT is a theory that focuses on the 476 "workability" of complex interventions in the real world.44 We hypothesise that PEH may be 477 "overwhelmed" by self-management tasks and will vary in their capacity to cope with any given level of 478 treatment burden depending on a range of factors such as health literacy, language, drug seeking behaviour, 479 level of educational attainment, personal beliefs, physical and mental abilities, and structural and practical 480 barriers to accessing care. We will be looking at the issue of treatment burden with participants through a 481 NPT lens and considering how the intervention affects individual capacity. Findings will be considered 482 483 alongside quantitative outcomes (PETS, treatment burden measure) obtained as part of the secondary 484 outcome measures.

This qualitative work will enable us to capture rich, complex data and unanticipated insights. Data will be
 analysed using NVivo V.12 software.⁴⁵

487

488 Data monitoring

A multidisciplinary data monitoring committee involving researchers. NHS administrators and clinicians 489 490 will have oversight of the qualitative and quantitative data collection process, and study methods, independent from the main study funder (Drug Death Task Force of the Scottish Government). The data 491 492 monitoring committee will ensure researchers have access to relevant data, and study milestones are adhered 493 to. No interim analyses are planned, and as the study intervention is offered in addition to usual care, with PHOENIx supporting patients using guideline based care only, adverse events of the trial intervention are 494 not anticipated. Trial conduct will be audited by NHS Greater Glasgow and Clyde Research and 495 496 Development, independent from the study investigators.

497

498 Ethical approval and trial registration

The trial is registered with the UK Clinical Trials Registry (ISRCTN 10585019), and was approved by the
South East Scotland Research Ethics Committee 01 and subsequently, governance approval by NHS
Greater Glasgow and Clyde Research and Innovation. The authors confirm that all ongoing and related
trials for this intervention are registered.

503

504 **Discussion**

Homelessness is a growing global public health problem associated with many adverse health outcomes,
 yet research in this sphere, particularly empirical evidence of multiple health, vulnerability factors, social
 care problems, and RCT evidence for collaborative health and social care interventions, remains sparse.²

508

509 The pilot PHOENIx after overdose RCT aims to determine whether a subsequent definitive RCT of a 510 Pharmacist and third sector homeless outreach worker intervention is merited. The basis for this is 511 achievement of progression criteria comprising recruitment, retention, data collection, and establishment of

the pharmacist intervention together with any signal of reduction in emergency department presentationsfor overdoses or other causes.

514

515 Strengths of this pilot trial relate to its rigorous design including embedded qualitative process and economic evaluations. The intervention is complex, and phases of complex intervention testing are being 516 517 followed. The intervention is aligned with best practice recommendations in relation to assertive outreach, 518 integrated health and social care support, providing longer appointments to enable patients to discuss their 519 multiple issues. The extensive characterization of the patient population, recruited from 20 different 520 locations in Scotland's largest city, ensures a cross section of PEH. Follow up is longer than most previous 521 RCTs in homelessness. Outcomes are diverse, covering progression criteria for a subsequent randomised controlled trial, health care utilization, and objective and subjective health measures. However, limitations 522 relate to the fact that this pilot trial is being conducted in Scotland only, with a population of PEH that may 523 not be ethnically diverse. High levels of refusal to study participation and dropout leading to low numbers 524 at 6 and 9 month follow up could also potentially threaten the generalizability of study results but we will 525 526 be monitoring and reporting on this.

527

The PHOENIx pilot randomised controlled trial will provide new data and if objectives are met, seeks to 528 529 inform a subsequent definitive trial aiming to reduce ED presentations for non-prescription drug overdose and other reasons, by strengthening primary health and social care in the community. It will also provide 530 new knowledge about the characteristics of this patient population in terms of: the extent, nature of and 531 treatment uptake for multimorbidity; non-prescribed drug use; uptake of primary and secondary health and 532 social care; welfare benefits; treatment burden; subjective and objective measures of health including 533 quality of life; laboratory results; and the prevalence of frailty to help inform future clinical trials and service 534 delivery in this area. 535

536

538 **Declaration of interests**

539 Suitably anonymised and summarised data will be made available on reasonable request.

540

541 Access to data

542 The principal investigator, researchers and independent statisticians will have access to the final trial 543 dataset.

544

545 **Dissemination policy**

Trial results will first be communicated to participants individually, verbally or in writing, through existing 546 547 homelessness networks and accommodation providers. Healthcare, social care and third sector workers involved in the trial (GPs, ED staff, addictions staff and others) will receive a written summary of findings 548 with an offer to meet the Principal Investigator to discuss the results. Health and Social care / Homelessness 549 staff with a role in policymaking will receive a summary of results, and an offer of meeting to discuss any 550 implications. The study findings will be described by all of the research team in accordance with guidelines 551 552 for eligibility of authorship and submitted for publishing in a peer reviewed journal. There are no plans to involve professional writers. 553

554

555 End of study date

Processes for NHS research governance approvals were delayed during COVID-19 lockdown, leading to a delay in the trial start date. The end-of-study date is on the last day of 9 month follow up data collection (July 2022). Allowing time for data input to the trial database, summary and analysis, the final results will be available in the last quarter of 2022.

560

561 Conclusion

We expect this pilot RCT aimed at PEH with recent non-prescription drug overdose will determine whether a full RCT is justified and to provide valuable insights into the health and social care needs of this

- 564 marginalised population, while providing a signal of whether the complex PHOENIx health and social care
- 565 intervention improves outcomes.
- 566

567 Funding

- 568 NHS Greater Glasgow and Clyde and the Drug Deaths Task Force, Scottish Government. The study
- 569 design, funding, staff and governance are independent from commercial sponsorship of any kind.